Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SYNB1891 |
Synonyms | |
Therapy Description |
SYNB1891 is a non-pathogenic strain of Escherichia coli that express STING (TMEM173), in order to stimulate the anti-tumor response of the innate immune system (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SYNB1891 | SYNB-1891|SYNB 1891 | SYNB1891 is a non-pathogenic strain of Escherichia coli that express STING (TMEM173), in order to stimulate the anti-tumor response of the innate immune system (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04167137 | Phase I | SYNB1891 Atezolizumab + SYNB1891 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects | Terminated | USA | 0 |